Mark Zuckerberg Joins AI Drug Discovery Race with New Protein-Focused Model
Big Tech’s New Obsession Is AI Drug Discovery, Zuckerberg Is Latest To Join In
Image: Times Now News
Mark Zuckerberg, alongside Dr. Priscilla Chan's Biohub, has launched an AI model aimed at revolutionizing drug discovery through protein design. This initiative addresses the challenges of creating effective proteins for human health, contributing to a growing trend among tech leaders in biotech innovation.
- 01Zuckerberg's AI model focuses on designing proteins crucial for human health, particularly in energy production and immune system support.
- 02The model employs Evolutionary Scale Modelling (ESM) to analyze protein sequences shaped by evolution, potentially reducing the time and cost of lab testing.
- 03Dr. Priscilla Chan indicated that the AI tools developed will be open-source, allowing broader access for researchers outside their organization.
- 04Sam Altman has invested heavily in AI-driven biotech, including a $180 million investment in Retro Biosciences, which focuses on extending healthy human lifespan.
- 05The increasing involvement of tech giants in drug discovery is transforming the landscape of biotech, making it resemble a competitive AI arena.
Advertisement
In-Article Ad
Meta CEO Mark Zuckerberg, in collaboration with Dr. Priscilla Chan's research organization Biohub, has unveiled a new AI model targeting protein biology to enhance drug discovery. This initiative aims to tackle one of the significant challenges in biotechnology: the expensive and complex process of designing proteins that function effectively within the human body. The new system utilizes Evolutionary Scale Modelling (ESM) to analyze evolutionary patterns in protein sequences, enabling researchers to predict protein behavior and design more effective treatments without extensive lab testing. Dr. Chan expressed optimism about the model's potential to accelerate research in cancer and immune diseases, emphasizing that the AI tools will be made open-source for wider accessibility. Meanwhile, Sam Altman, CEO of OpenAI, has also made substantial investments in AI-driven biotech, including a notable $180 million funding for Retro Biosciences, which aims to develop treatments for age-related diseases. As more tech leaders enter the drug discovery field, the industry is increasingly resembling an AI-driven battleground rather than traditional pharmaceutical research.
Advertisement
In-Article Ad
The AI model's development could significantly enhance drug discovery processes, potentially leading to faster and more effective treatments for diseases.
Advertisement
In-Article Ad
Reader Poll
What do you think about the role of AI in drug discovery?
Connecting to poll...
Read the original article
Visit the source for the complete story.